A Prospective Randomized Controlled Trial of Mobile Medical Used for Management of Pregnant Women

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03748576
Collaborator
(none)
640
1
2
30.9
20.7

Study Details

Study Description

Brief Summary

A multicenter, randomized controlled trial was conducted to investigate whether health education and life style management through WeChat group chat was: 1. more effective in improving pregnancy outcomes in normal pregnant women. 2. more effective in controlling blood glucose (BG) than standard clinic prenatal care in women with GDM.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: telemedicine: management through WeChat group chat
N/A

Detailed Description

  1. Mobile technology and equipment based on Internet and communications technology have revolutionized the content and manner of social interaction and services. Mobile medical care has just started, the relevant platform and service is still immature, not standardized, poor satisfaction, low efficiency, its value and effectiveness of health management lack of clear theoretical support and data description. In this study, based on the multi-center prospective randomized controlled study, we constructed a large-scale maternal health service platform and a systematic standardized maternal health management model to carry out personalized maternal health management and mobile health services. Mobile medical effects validation, and further improve the mobile medical platform.

This study will verify the value of mobile health care for maternal health management, to establish a standardized standard mobile medical model, to further improve the level of domestic maternal health management and improve the quality of maternal and child health management.

  1. Most gestational diabetes mellitus (GDM) can be well controlled by health education and life style management, expecting a better pregnancy outcome. But standard clinic prenatal care which consist of clinic visit every two weeks may not give full play to the effects of GDM management. Telemedicine shows its potential to fill this gap. A multicenter, randomized controlled trial was designed to investigate whether health education and life style management through WeChat group chat was more effective in controlling blood glucose (BG) than standard clinic prenatal care in women with GDM. Women with GDM diagnosed by oral glucose tolerance test between 23-30+6 gestational weeks were randomized to a WeChat group chat-based blood glucose management group or routine clinic prenatal care. In PUMCH, investigators also equip CGM for m-health group allowing a more detailed BG information. The primary outcome was change of glycemic qualification rate during follow up period in both groups. The second outcome was pregnancy outcomes. Also, a case control study is designed to compare the glucose control status between rice-richen meal and wheaten-richen meal, and all other macronutrients and micronutrients are all calculated and same between two groups, which may provide more clues for type of carbohydrate recommendation for Chinese women with GDM.

Study Design

Study Type:
Interventional
Actual Enrollment :
640 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Clinical Research on Mobile Medical Used for the Management of Pregnant Women: a Randomized Control Trail
Actual Study Start Date :
Nov 1, 2017
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
May 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mobile technologies group

m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.

Behavioral: telemedicine: management through WeChat group chat
Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care

No Intervention: control group

Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.

Outcome Measures

Primary Outcome Measures

  1. weight gain during pregnancy [up to 40 gestatinal weeks]

    Participants record their body weight twice a month. Weight gain from third-trimester and the whole pregnancy period are calculated.

  2. Glycemic qualification rate in women with GDM [From enrollment to 42 days postpartum]

    Glycemic qualification rate was calculated by the number of BG within the control range /30*100%. BG control range were fasting BG (fasting and before-sleep BG)#95 mg/dL (5.3 mmol/L) and two-hour postprandial BG (post-breakfast, post-lunch, post-dinner BG)#120 mg/dL (6.7 mmol/L)

Secondary Outcome Measures

  1. The incidence rate of specific pregnant outcomes in both normal pregnant women and women with GDM [at delivery]

    pregnancy outcomes include delivery mode, premature rupture of the membranes, preterm birth, SGA, LGA and postpartum hemorrhage

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Aged between 18 and 45 years.

  • With singleton pregnancy

  • Diagnosed or not diagnosed as GDM by 75g oral glucose tolerance test (OGTT) and insulin treatment is not required assessed by multi-disciplinary consultation.

  • Be able to use smart phone for chatting, read and write basic Chinese.

  • Volunteer for research.

Exclusion criteria:
  • Pregnancies with diagnosed chronic disease

  • Pregnancies with other pregnancy complications except GDM

  • Pregnancies had recent trauma and treatment of glucocorticoids

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of ob gyn, Peking Union Medical College Hospital Beijing Beijing China 100730

Sponsors and Collaborators

  • Peking Union Medical College Hospital

Investigators

  • Study Director: liangkun ma, Peking union medical college hosiptal

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT03748576
Other Study ID Numbers:
  • JS-1012
First Posted:
Nov 21, 2018
Last Update Posted:
Jul 24, 2020
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 24, 2020